Cargando…
Tumor Inhibitory Effect of IRCR201, a Novel Cross-Reactive c-Met Antibody Targeting the PSI Domain
Hepatocyte growth factor receptor (HGFR, c-Met) is an essential member of the receptor tyrosine kinase (RTK) family that is often dysregulated during tumor progression, driving a malignant phenotypic state and modulating important cellular functions including tumor growth, invasion, metastasis, and...
Autores principales: | Park, Hyunkyu, Kim, Donggeon, Kim, Eunmi, Sa, Jason K., Lee, Hee Won, Yu, Suji, Oh, Jiwon, Kim, Seok-Hyung, Yoon, Yeup, Nam, Do-Hyun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5618617/ https://www.ncbi.nlm.nih.gov/pubmed/28902178 http://dx.doi.org/10.3390/ijms18091968 |
Ejemplares similares
-
cIRCR201-dPBD, a Novel Pyrrolobenzodiazepine Dimer-Containing
Site-Specific Antibody–Drug Conjugate Targeting c-Met
Overexpression Tumors
por: Min, Byeongkwi, et al.
Publicado: (2020) -
Inhibitory effects of SEL201 in acute myeloid leukemia
por: Kosciuczuk, Ewa M., et al.
Publicado: (2019) -
Targeting the epithelial to mesenchymal transition in glioblastoma: the emerging role of MET signaling
por: Lee, Jin-Ku, et al.
Publicado: (2014) -
Immunomodulatory Effects of ZYM-201 on LPS-stimulated B Cells
por: Lee, Ye Eun, et al.
Publicado: (2014) -
High-Content Analysis-Based Sensitivity Prediction and Novel Therapeutics Screening for c-Met-Addicted Glioblastoma
por: Oh, Jeong-Woo, et al.
Publicado: (2021)